Log In
Print
BCIQ
Print
Print this Print this
 

CD3xCD123 DART molecule (MGD006)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD3 and CD123 developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD3
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today